News

Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company specializing in the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases, has just announced it has been invited to present at this week’s 17th Annual BIO CEO & Investor Conference. The conference, which will take place from February 9 to…

UK-based non-profit organization, Cystic Fibrosis Trust, recently launched a new awareness campaign that seeks to empower individuals living with cystic fibrosis (CF) to find out which specific CFTR gene mutation they are carrying. When patients know their specific mutation, physicians can prescribe more targeted, effective treatments, and even help patients participate in appropriate clinical…

A new report on cystic fibrosis (CF) in England and Wales further supports evidence of the groundbreaking impact that Kalydeco (ivacaftor) has had on treating CF, and reinforces the Cystic Fibrosis Trust‘s urgency for the drug to be made available to the 44 patients with rare CF gene mutations in…

The Cystic Fibrosis Foundation, a nonprofit donor-supported organization and world leader in the search for a cystic fibrosis cure, recently issued guidelines on the diagnosis and treatment of the disease. These guidelines were conceived by a committee of experts based on the available literature and clinical evidence reported.